Floyd Taub, MD

Founder and CEO of aiGENE, Inc. a DNA diagnostics company focused on developing the first methods that allow analysis of cancer DNA in the blood (ctDNA) to be a routine,inexpensive, accurate, almost universal test, available to monitor the success of cancer therapy in real time. aiGENE will develop methods appropriate for the clinical lab and the doctor's office.

• In-licensed, novel technology from UniQuest
• Filed multiple patents on improved and new ctDNA methods
• Filed a patent on a novel clinical trial design that increases approval rate and speeds drug development and reduces its cost
• Raised over $1 million to finance the company, including grants leveraging private investment.

CEO of AxImmune.

• Led clinical operations, quality improvement, productivity, risk management, university collaborations, and recruitment.
• Co-authored American Association of Cancer Research "late breaking" submissions presented in April 2017 and 2018. Combination checkpoint inhibitor therapy: Anti-PD1 and Beta-alethine lead to complete responses of melanoma in a syngeneic mouse model and Enhancement of Checkpoint Inhibitor Therapy by Beta-Alethine
• Podium presentation at Cambridge Health Institute's Drug Discovery Chemistry Conference 2018. "A Small Molecule Multiple Checkpoint Inhibitor"
• Ax 101 has been shown to decrease markers of severe checkpoint inhibition including PD1, Tim 3 and Lag 3. This correlates with tumor inhibition in animals of myeloma, melanoma, bladder cancer and breast cancer. It also correlates with all human Phase I/II lymphoma patients who are immune eligible meeting irRECIST and some meeting classic RECIST. The Chi-squared for complete remission p < 0.0001 in animal melanoma studies in combination with anti-PD1 while, anti-PD1 alone was not distinguishable from the PBS control.

President of AccuBiome

• Initiated a program using the instrument for vaginal biome evaluation
• Devised methods for rapid diagnosis of vaginitis pathology leading to preterm birth.

CureImmune
CEO/Founder
2005-Present

Developer of scientifically proven immune modulating therapies.

• Initiated sales of an OTC product line based on a novel drug.
• Out licensed to a larger company for up-front payments, royalty payments and a commitment to a major marketing campaign.

CytoCore (CYOE)
CEO
2007

Developer of diagnostic and therapeutic products for genitourinary cancers.

• Revised regulatory strategy, eliminated the need for additional trials prior to approval of first product.
• Cut time to approval by 2-3 years.

Dovetail Technologies & LifeTime Pharmaceuticals, Inc
CEO/Founder
1992-2005

Small businesses focused on “fast tracked” small molecules designed to treat life-threatening diseases.

• In-licensed university technology.
• Completed preclinical efficacy studies, preclinical toxicology, GMP manufacturing, and all IND enabling testing.
• Conducted Phase I/II clinical trials of Beta LT™ (beta-alethine).
• First in Class. The first clinical trial for checkpoint inhibition. Beta LT was the first compound that decreases (indirectly) immune checkpoint inhibition.

Digene Diagnostics, Inc
Founder/CEO/VP of R&D
1984-1990

• Identified the need for and then conceived, designed, developed, and marketed diagnostic tests to supplement and/or replace the inaccurate "PAP" smear. The Digene test has been approved as part of both routine screening and standard of optimal care.
• Digene, was the first provider of an FDA approved diagnostic for HPV typing. Its monopoly lasted ~20 years. Digene was resold to Qiagen for $1.6 billion in 2007.
• Negotiated a corporate partnership with Mitsubishi Petrochemical Company, Ltd., to fund R&D and to distribute Digene’s products in Japan.
• Conceived, wrote, and executed numerous research grants and contracts under the Small Business Innovative Research (SBIR) program. 100% success rate on Phase II applications.
• Designed and outfitted 3 facilities, including a 9,500 sq. ft. R+D facility and a 10,000 sq. ft. manufacturing facility.
• In 2021 HPV testing was independently deemed a suitable replacement for, as well as supplement to, the PAP smear for cervical cancer screening

Laboratory of Oral Medicine, National Institute of Dental Research, National Institutes of Health
Head, Pathology Unit
1982-1984

The unit specialized in the use of human monoclonal antibodies (derived by hybridoma technology and EBV transformation) in pathology and in the study of autoimmunity. Several of these antibodies were evaluated as clinical diagnostic tools for detecting and evaluating cancers.

Veramarx
Chief Scientific Officer
2014-2016

Designed and implemented a patented immunoassay using ten inflammatory biomarkers to diagnose chronic Lyme Disease/Post Lyme Syndrome.

• Developed a unique novel assay for diagnosing Post Lyme Syndrome
• Brought in new collaborators and a new hospital
• Validated the testing method and was able to diagnose Post Lyme Syndrome with AUC > .90

Zetiq. Inc
Chief Medical Officer
2009-2011

Zetiq developed a proprietary diagnostic platform, CellDetect, for the detection of cancer via discriminate staining of cancer vs. normal cells, preserving the morphological features of the cells. The method is based upon their altered metabolism.

Eveia Medical
Chief Medical Officer
2009

Diagnostic company with unique POC and central laboratory diagnostics.

• Defined initial indication for the first close to market anemia product.
• Investigated new format of immunoassay that achieves a separation step in solution.

OTraces
Chief Medical Officer 2008-2009

Company developed oligo-analyte screen including host response and cancer biomarkers with AUC >.95 for cancers including breast and prostate cancer.

• Refined regulatory strategy.
• Revised clinical trial strategy

TRAINING & LICENSING

• Northwestern University Medical School - Honors Program in Medical Education B.A.;M.D.
• University of Colorado - Pathology Internship and Residency
• George Washington University - Pathology Fellowship
• Diplomat of the American Board of Pathology
• Licensed in California

Research Associate, National Cancer Institute, Laboratory of Biochemistry
1978-1981:

(Chiefs: Robert Goldberger, M.D., and Maxine Singer, Ph.D.), Biochemistry of Gene Expression Section (Head: E. Brad Thompson). Studies on the control of glucocorticoid inducible genes. The methods used included recombinant DNA technology, somatic cell hybridizations, enzyme purification, antibody production, and solution and filter hybridization of nucleic acids. This work included differential screening of a rat liver cDNA library to directly identify clones containing glucocorticoid-induced or -repressed RNA sequences.

Developed a unique system using computerized image processing, enhancement, and quantification to evaluate gene expression (Genomics) via solution-solid phase hybridization to each member of a cDNA library. This technology allowed detailed study of gene regulation and isolation of specific recombinant clones. This new system is the nucleic acid counterpart of comparative two-dimensional protein gel electrophoresis.

Autopsy Supervisor, University of Colorado Medical Center.
1976-1978:

Designed the program and was responsible for supervising the autopsy-related work of up to 12 physicians. Favorable evaluation led to the program's continuation after his tenure at UCMC ended.

Research with Paul Nakane, Ph.D., Pathology Department, University of Colorado Medical Center. Differentiation of pituitary cells following endocrine manipulation in vivo was studied. Techniques used included multiple peroxidase-labeled anti-hormone antibodies and flow microfluorometry.

Research with Terry Johnson, Ph.D., Department of Microbiology, Northwestern University Medical School.
1974-1976

(Dr. Johnson is now Professor/Director of the Division of Biology, Kansas State University.) A model system for pediatric brain damage in the genetic disease phenylketonuria (PKU) was examined. Nucleic acid and protein biochemistry defined the molecular site of inhibition of protein synthesis in immature rat brain following phenylalanine overloading. Based on this work, a new therapeutic approach was devised. This approach was effective in an animal model of PKU.

1971: National Science Foundation Research Participation Program Grantee
1971

for work with Aryeh Routtenberg, Ph.D., at Northwestern University Psychology Department. A novel method for determination and documentation of functional relationships between structurally diverse CNS regions was devised.

1968-1969: Research and study under Rulon Rawson, M.D., Vice President and Dean, New Jersey College of Medicine and Dentistry.
1968-1969

In vivo studies of induction of red blood cell production by erythropoietin (epo) following radiation injury were performed. This work led to a Special Army Science Award. Epo class drugs have a market of over $5 billion and for many years been the best selling biotechnology drugs. The are used to treat fatigue. However unlike the drugs Dr. Taub has recently developed their use is limited to those with anemia.

Representative Invited Presentations:

• Cambridge Healthtech Institute, Baltimore, MD
• Cambridge Healthtech Institute, Tyson's Corner, VA
• A-T Children's Project, Longwood Gardens, PA
• Northwestern University, Evanston, IL
• Biogen, Geneva, Switzerland
• University of Chicago
• University of California-Los Angeles
• George Washington University, Washington, DC
• Bethesda Research Laboratories, Bethesda, MD
• Diabetes Telethon
• Physicians Radio Network
• XI Congreso de Investigacion Cientifica, San Juan, Puerto Rico
• Society for Industrial Microbiology annual meeting, Baltimore, MD
• Dental Research Programs Advisory Committee, NIH, Bethesda, MD
• Baxter Healthcare Corporation, Deerfield, IL
• Montana Society of Pathologists, Great Falls, MT
• University of Texas Medical Branch, Galveston, TX
• Congressional subcommittee hearing on Technology Transfer, Washington, DC
• Portfolio Management for the Biotech Industry, San Diego, CA

Societies (not all current):

• Academy for the Advancement of Medicine
• American Academy of Anti-Aging Medicine
• American Association for the Advancement of Science
• American Association for Clinical Chemistry
• American Society of Hematology
• American Society for Microbiology, American Society of Clinical Pathologists
• Foundation for Advanced Education in the Sciences
• International Academy of Pathology
• New York Academy of Sciences
• Sigma Xi
• Society for Biological Therapy
• Honored Member Strathmore's Who's Who 2000-2001 (Millennium Edition)
• The Official ABMS Directory of Certified Medical Specialists.

Historic Review of Medical Training

1970-1976	Entered Northwestern University's Honor Program in Medical Education directly from high school.  1974, B.S.  1976, M.D.
1975	Commissioned Jr. Assistant Surgeon, United States Public Health Service.
1976-1978	Anatomic pathology internship and residency, University of Colorado Medical Center.  Subspecialty: endocrine pathology. Training included ultrastructural, immunohistochemical, surgical, and autopsy pathology.  Autopsy supervisor, January to June, 1978.
1980	Promoted to Full Surgeon, United States Public Health Service.
1981-1982	Surgical Pathology Fellow, George Washington University.
1982	Diplomat of the American Board of Pathology.

Current license to practice medicine in California.
More than 50 publications in scientific literature. Inventor or co-inventor on seven biomedical patents/applications.

Publications (Papers):

Publications (Abstracts):

1. Sutherland DER, R Sibley, P Chinn, A Michael, S Srikanta, F Taub, J Najarian, FC Goetz (intr. by JH Oppenheimer). Twin-to-twin pancreas transplantation (TX): reversal and reenactment of the pathogenesis of type I diabetes. Clinical Research, 1984; 32:561A.
2. Taub FE, J Scharff. Assay of islet cell antibodies (ICA), a more sensitive method. Diabetes, 1984; 33 (Suppl. 1):63A.
3. Yoon JW, JS Scharff, CJ Bachurski, TH Lee, FE Taub. Antibody to islet cell antigens from patients with Vacor induced insulin-dependent diabetes mellitus. Diabetes, 1984; 33 (Suppl. 1):161A.
4. Katial A, K Roshto, T Higgs, F Taub. Peroxidase labeled nucleic acid probes. Poster presented to the American Society of Biological Chemists, Washington, DC, 1986.
5. Taub F, H Rutherford. Processing images of radioautographs to analyze nucleic acid hybridizations: a computerized method to study multiple gene expression.  Poster presented to the American Society of Biolgoical Chemists, Washington, DC 1986.
6. Katial A, K Roshto, E Cantin, F Taub. Detection of herpes virus using peroxidase labeled nucleic acid probes. Poster presented at the 1st Annual ASM Conference on Biotechnology, Washington, DC, 1986.
7. Roshto K, T Higgs, A Shaikh, J Saba, F Taub. Background reduction in filter hybridizations. The use of direct nucleic acid horseradish peroxidase conjugates. Poster presented to the American Society of Biological Chemists, 1987.
8. Grillo S, M Mosher, P Charles, S Henry, F Taub. DNA/DNA in situ hybridization with enzyme linked probes.  Poster presented to the American Society of Biological Chemists, 1987.
9. Grillo SL, CM Bruns, ME Mosher, FE Taub. The use of direct DNA-peroxidase conjugates for rapid, non-radioactive detection of HPV sequences by in situ hybridization. Poster presented at the 6th International Papillomavirus Workshop, Washington, DC, 1987. Published in Abstracts of Papers Presented at the Sixth International Papillomavirus Workshop, p.105.
10. Mosher ME, SL Grillo, N Moore, A Maters, R Ambinder, FE Taub. Rapid detection of herpesviruses by in situ hybridization with enzyme-linked probes. Poster presented at the 12th International Herpesvirus Workshop, Philadelphia, PA, 1987.
11. Mosher ME, SL Grillo, N Moore, A Maters, M Forman, R Ambinder, FE Taub. Rapid detection of virus-infected cells by in situ hybridization using DNA probes directly linked to active enzymes.  Poster presented at Gene Probe Technology II: 1987 American Association for Clinical Chemistry San Diego Conference.
12. Mosher M, A Maters, D Jones, M Forman, S Grillo, F Taub. Rapid detection of cytomegalovirus-infected cells by in situ hybridization with enzyme-linked DNA probes. Abstracts of the Annual Meeting of the American Society for Microbiology, 1988, p.320.
13. Bruns CM, C Cardozo, CR Ceccarelli, L Corey, JM Douglas, SL Grillo, A Langenberg, J Saba, FE Taub. Rapid in situ hybridization to HPV DNA sequences in cervical smears using direct enzyme-labeled DNA probes. Poster presented at the 7th International Papillomavirus Workshop, Sophia Antipolis, France, 1988. Published in Seventh International Papillomavirus Workshop, p.30.
14. Taub, F. In situ hybridization in surgical pathology. Talk given at George Washington University, Washington, D.C. on May 7, 1988, as part of the series, "Advances in Surgical Pathology."
15. Higgs T, N Moore, G Gamerman, C Bruns, D Badawi, F Taub. Highly sensitive, rapid, and specific detection of HPV types 6/11 and 16/18 in formalin-fixed paraffin-embedded sections using directly conjugated HRP-labeled DNA probes.  Poster presented at the 8th International Papillomavirus Workshop, Taos, NM, 1989. Published in Journal of Cellular Biochemistry, Suppl.13C, 1989, p.187.
16. Bruns CM, CR Ceccarelli, J Summerville, T Higgs, FE Taub. Type-specific HPV detection in Pap smears by in situ hybridization with enzyme-DNA conjugates. Poster presented at the 8th International Papillomavirus Workshop, Taos, NM, 1989. Published in Journal of Cellular Biochemistry, Suppl.13C, 1989, p.182.
17. McClintock JT, A Friedman-Kien, F Taub. Direct detection of Epstein-Barr virus in tongue tissue smears from individuals with suspected hairy leukoplakia.  Poster presented to the American Society for Microbiology, New Orleans, LA, 1989. Published in Abstracts of the 89th Annual Meeting of the American Society for Microbiology 1989, p.373.
18. Wacker WK, JT McClintock, S Strohofer, S Kahn, RP Baughman, FE Taub. Direct detection of cytomegalovirus in bronchoalveolar lavages using HRP-labeled DNA probes and in situ hybridization.  Poster presented to the American Society for Microbiology, New Orleans, LA, 1989. Published in Abstracts of the 89th Annual Meeting of the American Society for Microbiology 1989, p.373.
19. Badawi D, M Garcia, T Higgs, C King, S Yang, F Taub. Direct-labeled DNA probes for rapid viral diagnosis. Poster presented to the Society for Pediatric Pathology, Aspen, CO, 1989.
20. King PC, WK Wacker, RP Robinson, J Colandrea, R Robinson, FE Taub. Direct detection of CMV in bronchoalveolar lavage specimens using in situ hybridization. Poster presented to the Pulmonary Pathology conference sponsored by the Washington Hospital Center, Washington, DC, 1989.
21. King C, W Wacker, R Baughman, J Colandrea, R Robinson, B Weinstein, F Taub. CMV detection in cytologic and histologic specimens, using direct-labeled DNA probes and in situ hybridization. Poster presented at The International Academy of Pathology, Boston, MA, 1990. Published in Modern Pathology 3:52A, 1990.
22. King C, W Wacker, R Baughman, J Colandrea, R Robinson, B Weinstein, F Taub. CMV detection in cytologic and histologic specimens, using direct-labeled DNA probes and in situ hybridization. Poster presented at The International Academy of Pathology, Boston, MA, 1990. Published in Modern Pathology 3:52A, 1990.
23. Taub F, C King, T Higgs. Viral identification in situ with direct-labeled DNA probes. Poster presented at the UCLA symposium "Animal Models of Human Viral Diseases: Relevance to Developmental Therapeutics," Keystone, CO, 1990.
24. Taub F, S Thaker, H Salim, M Wesoloski, D Badawi. "Single copy detection" of HPV16 in SiHa cells with direct HRP-DNA probes. Poster presented at Papillomavirus Workshop 1990, Heidelberg, Germany, 1990.
25. Taub F, JS Park, D Badawi, K Shah. DNA-HRP probes reveal different morphological patterns of HPV distribution in benign and malignant neoplastic lesions. Poster presented at Papillomavirus Workshop 1990, Heidelberg, Germany, 1990.
26. Miller W, Caplan S, Shustik C, McQuillan A, Sicilia F, Batist G, Mayerson S, Taub F. Toxicity and Biological Effects of Beta-alethine - Report of the First Phase I/II Study. Poster presented at VII International  Multiple Myeloma Workshop 1999, Stockholm, Sweden 1999.

Publications concerning Beta-alethine:

1. Taub, F. Beta-alethine (Beta LT): A Low Molecular Weight Cytokine Inducer with Anti-Cancer Properties and Low Toxicity in Mice and Man? Review of Data to Date. Poster presented at Cancer Immunosurveillance 1999 - Cancer Research Institute, New York, New York 1999.
2. Taub F, Mayerson S, McQuillan A, Caplan S, Shustik C, Miller W. Phase I/II Evaluation of Beta LT as an antilymphoma agent and enhancer of DTH in lymphoma patients. Poster presented at The International Conference on Molecular Targets and Cancer Therapeutics, Washington, D.C. 1999.
3. Miller WH, Caplan S, Shustik C, McQuillan A, Sicilia F, Mayerson S, Taub F. Beta-alethine Immunomodulation in Follicular B Cell Lymphoma and Multiple Myeloma: Initial Phase I/II Results. Submitted. Blood Supplement (Part II), November 15, 1999.
4. W.H. Miller, Jr., S. Caplan, C., Shustik, A. McQuillan, F. Sicilia, S. Mayerson and F. Taub. Beta-alethine: TNF alpha, Antitumor Effects and Delayed Type Hypersensitivity in Follicular B-Cell Lymphoma. Oral presentation at the ISH 2000 (28th International Congress) Toronto, Ontario, August 2000.
5. F. Taub. Review of Beta LT immunomodulation in lab studies and patients with follicular B cell lymphoma: Initial phase I/II results.  Presented at the Comprehensive Cancer Care 2000, Arlington, VA, June 2000.
6. F. Taub, K. Manos, S. Mayerson. A review of animal models and human clinical trial data supportive of beta-alethine (BT) immune therapy for minimal residual disease (MRD). Presented at the 15th Annual Scientific Meeting of the Society for Biological Therapy, Seattle, WA October 2000.
7. W.H. Miller, Jr., S. Caplan, C., Shustik, A.McQuillan, F. Sicilia, S. Mayerson and F. Taub.T cells exhibit increased TNF alpha and delayed type hypersensitivity responses are restored in patients with B cell malignancies following administration of beta-alethine. Presented at the American Association for Cancer Research, 11th NCI-EORTC-AACR Symposium Amsterdam, The Netherlands, November 2000.
8. C.H. Pontzer and F. Taub.Reducing toxicity of recombinant biomolecules through engineering. Presented at the Cambridge Healthtech Institute Recombinant Therapeutics: Antibodies and Biomolecules Conference, Baltimore, MD, June 2001.

Patents:

1. Taub F. Assay for Nucleic Acid Sequences, Particularly Genetic Lesions, Using Interactive Labels.
2. Taub F. Bifunctional DNA-Protein Conjugating Agent.
3. Taub F, Higgs TW, Roshto K.Macromolecular Conjugate.
4. Higgs TW, Taub F. A Highly Sensitive Method for Detecting Peroxidase.
5. Taub FE, Lazar J. Macromolecular Conjugate Made by  (confidential).

Scientific Presentations, Conferences and Public Relations in 2003 & 2004 for Taurox

• Fatigue Reduction and Quality of Life Enhancement Following Therapy with Taurox. (Presentation at Exeter University (UK) December 2006) Floyd E. Taub, M.D., Char Tara Albert, Lesley Crowder, Suzin Mayerson Wright, Ph.D.
• 11th Annual Meeting of the Society for Orthomolecular Health-Medicine (OHM) in San Francisco, California, February 24-27, 2005, Fatigue Reduction Due to Changing Cytokine Patterns. Immunostimulation by COBAT (Taurox SB) in Patients with Lyme Disease
• KFNX News Talk Radio, August 8th, 2004, 8:00 a.m. PST
  Floyd Taub, M.D. was interviewed by Dr. Warren Levin, Host of the show, "Third Opinion"
• Familynet Television Interview June 17 and 25, 2004
  BioInnovations produces a daily television show for the Familynet cable network, which broadcasts to over 30-million viewers mainly in the Midwest and South, hosted by Dr. Richard Becker and his wife Cindy. Allergy Research Group, one of Dovetail's distributors introduced the Beckers to Dr. Floyd Taub, Dovetail Technology's Chairman and Chief Medical Officer.  Dr. Taub participated in two 30-minute television shows on June 17, 2004 discussing Taurox research. One aired live on Familynet Television that day, the second program aired on June 25, 2004. Familynet is a television service dedicated to health and family matters and provides holistic medical information that is generally not available to its audience other than through Dr. Becker.
• Health Sciences Institute (HIS) Newsletter, May 2004 Issue
  HIS published an article entitled 'What the Goldilocks effect' can do for fatigue and your immune system , covering Taurox research and products.

Sample Presentations by Dr. Floyd Taub:

• Society For Orthomolecular Health-Medicine, 11th Annual Scientific Meeting, About Lyme: Testing, Diagnosis, Therapeutic Protocols, February 27, 2005, San Francisco, California, Fatigue Reduction Through Changing Cytokine Patterns.
• American Academy of Environmental Medicine 39th Annual Meeting, October 28 - 31, 2004, Hilton Head Island, South Carolina. Taurox SB - the First Available NanoDrug
• Fourth World Conference on Nutritional Medicine in San Francisco, California American Association for Chronic Fatigue Syndrome, Sixth Biennial. May 28, 2004,  Taurox and NanoDrugs
• International College of Integrative Medicine International Congress, September 10-September 14, 2003, St. Louis, MO.  Beta Alanine Containing NanoDrugs in the Treatment of Fatigue in Patients with Chronic Fatigue Syndrome Cancer, and HCV.
• First International Conference on Whole Person Healing, March 28-March 30, 2003, Washington, DC. Immunomodulator Taurox SB Reduces Fatigue in Patients with Cancer, HCV and Chronic Fatigue Syndrome.
• International Research and Clinical Conference, January 31-February 2, 2003, Chantilly, VA. Therapy with the Cytokine Modulator Is Associated with Decreased Fatigue in Patients with Chronic Fatigue.

Listing of Scientific Research concerning Taurox

1. Taurox SB -- Molecular Activity, Safety, and Efficacy, Taub, F.E.
2. Data on Fatigue, Allergies and Hepatitis from Structured Case Histories and Clinical Outcome Trials of Taurox
3. Taurox Clinical Trials Protocol
4. In Vitro Cell Culture In Media Containing Beta-Alanyl-Taurine or Carbobenzoxy Beta-Alanyl-Taurine, Knight, G. D., Scanlen, T. J., University of New Mexico, Issued U.S. Patent Number 6,323,025 B1, November 27, 2001
5. In Vitro Cell Culture In Media Containing Beta-Alanyl-Taurine or Carbobenzoxy Beta-Alanyl-Taurine, Knight, G. D., Scanlen, T. J., University of New Mexico, Issued U.S. Patent Number 6,096,536, August 1, 2000
6. The Anticancer Properties of Taurox SB may be Mediated by an Immunostimulatory Mechanism, Dunn, T.M., Wormsley, S., Taub, F.E., and Pontzer, C.H. Abstract presented at the American Society for Pharmacology and Experimental Therapeutics.
7. The Immunostimulatory Effects of Taurox SB, Dunn, T. M., Taub, F. E., Pontzer, C H., Department of Cell Biology and Molecular Genetics, University of Maryland, Submitted for publication 2001
8. Thesis on the Immunostimulatory Effects of Taurox SB, Dunn, T. M., Department of Pharmacology and Experimental Therapeutics, University of Maryland at Baltimore School of Medicine, 2000
9. Therapeutic Use of Vitalethine Modulators in Neoplasis, Knight, G. D., Scanlen, T. J., University of New Mexico, Issued U.S. Patent Number 5,578,313, November 26, 1996
10. Therapeutic Use of Vitalethine Modulators in Neoplasia, Knight, G. D., Scanlen, T. J., University of New Mexico, Issued U.S. Patent Number 5,370,868, December 4, 1994
11. Vitalethine Modulates Erythropoisis and Neoplasia, Knight, G. D., Laubscher, K. H., Fore, M. L., Clark Scanlen, T. J., Cancer Research, 1994; 54(21): 5623-35

Taurox Monograph and Toxicology Documents Available

1. Addendum to Toxicology Monograph on Taurox SB, Rice, S. A., April 1, 2002 (Confidential)
2. Taurox SB Review Of Dr. Susan Rice's Toxicology Monograph And Response To 4 November 2001 MRC Meeting Report Questions, Hood, R. D., March 29, 2002 (Confidential).
3. Comparison of Toxicity Risks of Five Common Homeopathic Drugs and Taurox SB, Foxman, E. L., October 23, 2001 (Confidential)
4. Proving Report Taurox SB, Riley, D., Integrative Medicine Institute, 2001 (Confidential)
5. Toxicology Monograph on Taurox SB, Rice, S. A., September 13, 2001 (Confidential)
6. Taurox Monograph Submissions, May 2001 and September 2001 (Confidential)